Peptaluvéra products have not been evaluated by the U.S. Food and Drug Administration (FDA). No product sold by Peptaluvéra has been submitted to the FDA for review, approval, clearance, or authorization under any regulatory pathway, including but not limited to New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Biologics License Applications (BLA), Investigational New Drug Applications (IND), or 510(k) premarket notifications.

Peptaluvéra products are not intended to diagnose, treat, cure, mitigate, or prevent any disease, disorder, or medical condition in humans or animals. This applies to all products offered by Peptaluvéra, regardless of the peptide sequence, molecular structure, or any similarities to compounds referenced in published scientific or medical literature.

Peptaluvéra products are not manufactured under FDA current Good Manufacturing Practice (cGMP) regulations applicable to finished pharmaceuticals (21 CFR Parts 210 and 211), biologics (21 CFR Part 600), or dietary supplements (21 CFR Part 111). Our manufacturing and quality control processes are designed to meet the standards appropriate for research-grade laboratory reagents. Products are accompanied by a Certificate of Analysis reflecting analytical testing conducted under research reagent quality standards.

Peptaluvéra’s use of “Research Use Only” (RUO) labeling is consistent with FDA’s established framework for products distributed for research purposes. Peptaluvéra’s labeling, marketing materials, website content, and distribution practices are designed to clearly and unambiguously communicate that all products are intended for laboratory research use only.

Peptaluvéra recognizes that the FDA determines a product’s intended use based on the totality of evidence, including product labeling, promotional materials, advertising, marketing claims, oral and written statements, and the circumstances of distribution. Peptaluvéra maintains that its intended use — across all channels and communications — is exclusively scientific research. Peptaluvéra does not market, promote, label, or distribute any product for clinical, therapeutic, diagnostic, cosmetic, or dietary use.

Peptaluvéra does not provide dosing information, administration protocols, reconstitution instructions for injection or consumption, cycle recommendations, or any other guidance that could imply use in human or animal subjects. Product handling instructions provided by Peptaluvéra (e.g., reconstitution for assay preparation, storage temperature recommendations) are provided exclusively in the context of laboratory research protocols.

For questions about Peptaluvéra’s FDA compliance posture, please contact:

Peptaluvéra — Regulatory Compliance
Email: contact@peptaluvera.com
Subject Line: “FDA Compliance Inquiry”